Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. BSX

Go back to Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies

March 2, 2022 8:08 AM EST

Jefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $90.00 (from $85.00) while maintaining a Buy rating.

The analyst commented, "Q4 Caplyta sales in mostly schizophrenia (SCZ) grew by +18% Q/Q to $25.5M (in line vs cons;... More

Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c

March 1, 2022 7:34 AM EST

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

... More